February 2017February 2017
New Product - Bi Eligard CP
Bi Eligard CP (leuprorelin + bicalutamide) contains leuprorelin a LHRH agonist and potent inhibitor of gonadotropin secretion when given continuously in therapeutic doses, and bicalutamide a nonsteroidal antiandrogen. Bi Eligard CP is indicated for the treatment of advanced prostate cancer in combination with LHRH agonist therapy (bicalutamide component) and for the palliative treatment of advanced prostate cancer (leuprorelin component). Bicalutamide is contraindicated in females and children, and with coadministration of terfenadine, astemizole or cisapride. Eligard (leuprorelin) is contraindicated with previous orchiectomy, pregnancy and lactation, and as a sole treatment in prostate cancer patients with spinal cord compression or evidence of spinal metastases. Bi Eligard CP is available as a combination therapy containing composite packs of Eligard (7.5 mg leuprorelin) subcutaneous implant plus 50 mg bicalutamide tablets 28’s; Eligard (22.5 mg leuprorelin) subcutaneous implant plus 50 mg bicalutamide tablets 28’s or 84’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au